GLP1R and Parkinson disease: The mental and behavioral mood of PD patients was evaluated using MDS-UPDRS I. There was no statistically significant difference between the GLP-1 agonists group compared to the control group which aligned with the previous systematic review made by Mulvaney et al. (2020).